Reuters logo
BRIEF-Sangamo receives fast track designation from FDA for SB-525
May 16, 2017 / 12:01 PM / 6 months ago

BRIEF-Sangamo receives fast track designation from FDA for SB-525

May 16 (Reuters) - Pfizer Inc-

* Sangamo receives fast track designation from the FDA for sb-525 investigational hemophilia a gene therapy

* Sangamo Therapeutics Inc says data from phase 1/2 clinical trial evaluating sb-525 in adults with hemophilia a expected in late 2017 or early 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below